Mariona Graupera
@grauperalab.bsky.social
Vascular biologist, vascular malformations and genetic mosaicisims
Thank you for inviting me, and for hosting me that well. If you are a vascular biologist, and you are thinking to come next year to IVBM in Adelaide, do not think it twice, this is a vibrant society ❤️!
Thrilled to welcome our first plenary speaker Mariona Graupera @grauperalab.bsky.social - beautiful work on endothelial cell plasticity in obesity and PIK3CA-driven vascular malformations
October 26, 2025 at 6:12 AM
Thank you for inviting me, and for hosting me that well. If you are a vascular biologist, and you are thinking to come next year to IVBM in Adelaide, do not think it twice, this is a vibrant society ❤️!
Reposted by Mariona Graupera
🥳🥳 We have more than 100 abstracts submitted for #GRC_Angiogenesis!!! Application deadline is TOMORROW!! don't miss it!
June 28, 2025 at 7:10 AM
🥳🥳 We have more than 100 abstracts submitted for #GRC_Angiogenesis!!! Application deadline is TOMORROW!! don't miss it!
We have an open postdoc position to work on PTEN and vascular Malformations. If you are intersted, apply: careers.carrerasresearch.org/jobs/6107690...
VAC_53_2025 - POSTDOCTORAL RESEARCH - Institut de Recerca contra la Leucèmia Josep Carreras
Join the Josep Carreras Leukaemia Research Institute and contribute to our mission of innovating and advancing the fight against leukaemia and other hematologic diseases.
careers.carrerasresearch.org
June 27, 2025 at 3:22 PM
We have an open postdoc position to work on PTEN and vascular Malformations. If you are intersted, apply: careers.carrerasresearch.org/jobs/6107690...
If you are interested in vascular malformations you may want to check our new work published today in Cancer Discovery, where we discover a somatic genetic event causing vascular malformations in PTEN hamartoma tumor syndrome (PHTS) aacrjournals.org/cancerdiscov...
Somatic uniparental disomy of PTEN in endothelial cells causes vascular malformations in patients with PTEN Hamartoma Tumor Syndrome
Abstract. PTEN Hamartoma Tumor Syndrome (PHTS) is a rare tumor risk disorder caused by germline loss-of-function mutations in PTEN. Half of these patients develop vascular malformations, a hamartoma c...
aacrjournals.org
March 28, 2025 at 3:12 PM
If you are interested in vascular malformations you may want to check our new work published today in Cancer Discovery, where we discover a somatic genetic event causing vascular malformations in PTEN hamartoma tumor syndrome (PHTS) aacrjournals.org/cancerdiscov...
I rising star! I could not be prouder ❤️!
🎉 👩🔬 Ana Angulo-Urarte (@grauperalab.bsky.social) receives the Junior Leader Retaining grant from "la Caixa" Foundation
🔬 Her research will improve the understanding of how cells with mutations in the PIK3CA gene behave during embryonic development
🔗 www.carrerasresearch.org/en/news/ana-...
🔬 Her research will improve the understanding of how cells with mutations in the PIK3CA gene behave during embryonic development
🔗 www.carrerasresearch.org/en/news/ana-...
March 19, 2025 at 9:45 AM
I rising star! I could not be prouder ❤️!
Reposted by Mariona Graupera
EVBO is offering personalised #training for #EVBOmembers for ERC Starting Grant interview.
We want EVBO research to be funded by the ERC!
If interested, contact Prof. Taija Makinen @ taija.makinen@igp.uu.se by the 25th April.
More info: buff.ly/dexAhf7
We want EVBO research to be funded by the ERC!
If interested, contact Prof. Taija Makinen @ taija.makinen@igp.uu.se by the 25th April.
More info: buff.ly/dexAhf7
March 6, 2025 at 5:00 AM
EVBO is offering personalised #training for #EVBOmembers for ERC Starting Grant interview.
We want EVBO research to be funded by the ERC!
If interested, contact Prof. Taija Makinen @ taija.makinen@igp.uu.se by the 25th April.
More info: buff.ly/dexAhf7
We want EVBO research to be funded by the ERC!
If interested, contact Prof. Taija Makinen @ taija.makinen@igp.uu.se by the 25th April.
More info: buff.ly/dexAhf7
We are excited to share our work on Context-dependent response of endothelial cells to PIK3CA mutation. A tour the force of many; thank you all for your invaluable contribution. @aangulou.bsky.social @ruibenedito.bsky.social @debocklab.bsky.social @sandradcastillo.bsky.social
bit.ly/4blKSqa
bit.ly/4blKSqa
Context-dependent response of endothelial cells to PIK3CA mutation
Cancer mutations in the PIK3CA gene cause congenital disorders. The endothelium is among the most frequently affected tissues in these disorders, displaying aberrant vascular overgrowth in the form of...
bit.ly
February 26, 2025 at 12:19 PM
We are excited to share our work on Context-dependent response of endothelial cells to PIK3CA mutation. A tour the force of many; thank you all for your invaluable contribution. @aangulou.bsky.social @ruibenedito.bsky.social @debocklab.bsky.social @sandradcastillo.bsky.social
bit.ly/4blKSqa
bit.ly/4blKSqa
The freshly cooked video summarizing the Art project developed in the frame of our PIPgen MSCA DN: “PIPgenerating ART: Where Art meet Science “. A collaborative activitys between our students and the Cambridge School of Visual Performing Arts.
www.youtube.com/watch?v=tQxA...
www.youtube.com/watch?v=tQxA...
PIPgenerating ART: Where Art meet Science
YouTube video by PIPgen
www.youtube.com
November 23, 2024 at 6:46 PM
The freshly cooked video summarizing the Art project developed in the frame of our PIPgen MSCA DN: “PIPgenerating ART: Where Art meet Science “. A collaborative activitys between our students and the Cambridge School of Visual Performing Arts.
www.youtube.com/watch?v=tQxA...
www.youtube.com/watch?v=tQxA...
Reposted by Mariona Graupera
Published a few weeks ago in Cancer Research, we show benefit of targeting HMCR with pitavastatin in combo with AKT inhibitors in TNBC. Many amazing people contributed, led by the magnificently talented @alissandra-hillis.bsky.social! Looking to initiate new clinical trials based on this combo. 🧪
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer
Two FDA-approved compounds, AKT inhibitors and pitavastatin, synergize to induce cell death in triple-negative breast cancer, motivating evaluation of the efficacy of this combination in clinical tria...
aacrjournals.org
November 20, 2024 at 12:09 PM
Published a few weeks ago in Cancer Research, we show benefit of targeting HMCR with pitavastatin in combo with AKT inhibitors in TNBC. Many amazing people contributed, led by the magnificently talented @alissandra-hillis.bsky.social! Looking to initiate new clinical trials based on this combo. 🧪
Reposted by Mariona Graupera
Pls share 🌟Join the IMP as a Group Leader
We are 👀 for a colleague, ready to lead a groundbreaking research program. Enjoy generous funding, outstanding facilities & a vibrant scientific community in one of the world's most livable cities @impvienna.bsky.social
👉https://tinyurl.com/impgl2025
November 20, 2024 at 10:46 AM
Pls share 🌟Join the IMP as a Group Leader
We are 👀 for a colleague, ready to lead a groundbreaking research program. Enjoy generous funding, outstanding facilities & a vibrant scientific community in one of the world's most livable cities @impvienna.bsky.social
👉https://tinyurl.com/impgl2025
Beautiful as always ❤️
🥳 First Yaniv Lab paper to appear on this new platform!! Thanks Baptiste for the shout-out! 🎉
November 16, 2024 at 11:02 AM
Beautiful as always ❤️